CALL FOR PAPERS
Online abstract submission will be open on 1 February 2020. Deadline for submission is 15 May 2020.
Submission Timeline and Instructions
The Scientific Committee will review all abstracts, and you will be notified by 18 May 2020 whether your abstract has been accepted. The decision of the Scientific Committee is final. All abstracts accepted will be published in the program book that will be distributed to all conference attendees. Please note that you must register by 15 June 2020 for your abstracts to be published in the program book.
Submissions are welcome in the following categories:
Basic Science | Biomarkers | Breast Cancer | CNS Tumors | Developmental Therapeutics | Diagnostic Developments | Endocrine Tumors | Gastrointestinal Tumors | Genitourinary Tumors | Gynecological Tumors | Hematological Tumors | Head and Neck Cancers | Immunotherapy | Lung Cancers and Other Intra-thoracic Malignancies | Melanoma and Other Skin Cancers | Neuroendocrine Tumors | Palliative Care | Psycho-Oncology | Radiation Oncology | Sarcoma | Supportive Care | Surgical Oncology | Translational Research | Tumor Biology and Pathology | Miscellaneous Topics
Structure of Abstract
Abstracts must be submitted in English, not exceeding 500 words. The material for presentation should be unpublished and original.
Substitution/Withdrawal of Abstract Author
Due to program and publishing deadlines, withdrawal of abstract after 31 May 2020 is highly discouraged. Abstracts may be withdrawn during the submission period by emailing the BASCO Secretariat.
IRB approval is required for studies involving human subjects. For translational research studies involving animal subjects, authors are to adhere to animal ethics guidelines and institution IACUC approval must be granted.
Due to the developments of the COVID-19 situation and as a precautionary measure, BASCO 2020 will be postponed to 2021.
If you have submitted your abstracts, your submission will be transferred to BASCO 2021.
However should you wish to withdraw your abstract, please write in to us via our Contact Us page.